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The ComeÁl±Netherton syndrome is an autosomal
recessive multisystemic disorder characterized by
localized or generalized congenital ichthyosis, hair
shaft abnormalities, immune de®ciency, and markedly
elevated IgE levels. Life-threatening complications
during infancy include temperature and electrolyte
imbalance, recurrent infections, and failure to thrive.
To study the clinical presentations of the ComeÁl±
Netherton syndrome and its molecular cause, we
ascertained 19 unrelated families of various ethnic
backgrounds. Results of initial linkage studies
mapped the ComeÁl±Netherton syndrome in 12 multi-
plex families to a 12 cM interval on 5q32, thus con-
®rming genetic homogeneity of ComeÁl±Netherton
syndrome across families of different origins. The
ComeÁl±Netherton syndrome region harbors the
SPINK5 gene, which encodes a multidomain serine
protease inhibitor (LEKTI) predominantly expressed
in epithelial and lymphoid tissues. Recently, recessive
mutations in SPINK5 were identi®ed in several
ComeÁl±Netherton syndrome patients from consan-
guineous families. We used heteroduplex analysis
followed by direct DNA sequencing to screen all 33
exons and ¯anking intronic sequences of SPINK5 in
the affected individuals of our cohort. Mutation
analysis revealed 17 distinct mutations, 15 of which
were novel, segregating in 14 ComeÁl±Netherton syn-
drome families. The nucleotide changes included four
non-sense mutations, eight small deletions or inser-
tions leading to frameshift, and ®ve splice site defects,
all of which are expected to result in premature ter-
minated or altered translation of SPINK5. Almost
half of the mutations clustered between exons 2 and
8, including two recurrent mutations. Genotype±
phenotype correlations suggested that homozygous
nucleotide changes resulting in early truncation of
LEKT1 are associated with a severe phenotype. For
the ®rst time, we used molecular data to perform pre-
natal testing, thus demonstrating the feasibility of
molecular diagnosis in the ComeÁl±Netherton syn-
drome. Key words: atopic dermatitis/congenital recessive
ichthyosis/hair abnormalities/linkage analysis/serine pro-
teinase inhibitors. J Invest Dermatol 117:179±187, 2001
T
he ComeÁl±Netherton syndrome (NTS; MIM 256500)
is a rare autosomal recessive disorder of the skin, hair
and immune system ®rst reported by ComeÁl in 1949
and Netherton in 1958 (ComeÁl, 1949; Netherton,
1958). The syndrome presents at or soon after birth
with generalized erythroderma, scaling, and/or continuous peeling
of the skin resembling nonbullous congenital ichthyosiform
erythroderma (CIE; OMIM 242100) or peeling skin syndrome
(OMIM 270300). In about 20% of patients the neonatal period is
complicated by hypernatremic dehydration, electrolyte imbalances,
perturbed thermoregulation, failure to thrive and recurrent
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infections (Jones et al, 1986; Hausser et al, 1989; Traupe, 1989),
which may result in neonatal demise (de Wolf et al, 1995; Judge
et al, 1994; Smith et al, 1995; Judge and Harper, 1996). These
complications might, at least in part, be attributed to the collapse of
the epidermal barrier function (Fartasch et al, 1999). Whereas in
individuals with severe disease the generalized CIE-like features
persist throughout life, the ichthyosis in most patients gradually
evolves into migratory, serpiginous, scaling, and erythematous
plaques, which are bordered by a peculiar double-edged scale
descriptively named ichthyosis linearis circum¯exa (ILC) (Greene
and Muller, 1985; Traupe, 1989). The skin lesions are often
pruritic, resemble atopic eczema, and show an unstable, undulating
course. They are usually accompanied by hair shaft abnormalities
that develop during early childhood and may result in diffuse
alopecia. The hallmark of NTS is trichorrhexis invaginata (bamboo
hair), but other abnormalities, including pili torti (twisted hair) and
trichorrhexis nodosa (hair of varying diameter), have been
observed. Markedly elevated IgE levels, allergic reactions to food
and common antigens, malnutrition, and increased susceptibility to
skin, respiratory tract or systemic infections are also characteristic
(Sybert, 1997).
Although there are no more than 150 cases of NTS reported
in the literature, its true incidence might be as high as 1/50,000
(Traupe, 1989) due to challenging diagnostic problems during
infancy and early childhood and overlapping features with
atopic dermatitis (ILC type) and other recessive ichthyoses (CIE
type). A recent report indicating that up to 18% of congenital
erythrodermas are attributable to NTS lends support to this
assumption (Pruszkowski et al, 2000). Most patients with NTS
are sporadic cases; however, there are reports of affected sibships
(Dupre et al, 1978; Caputo et al, 1984; Kassis et al, 1986) and
of consanguinity in about 10% of the families with NTS, which
is consistent with autosomal recessive inheritance (Greene and
Muller, 1985).
The pathogenesis of NTS has engendered considerable
interest because of the peculiar association of skin, hair, and
immunologic abnormalities in the context of a monogenic
disorder. A mouse mutant with lance head-shaped hair, scaly
skin, and elevated IgE levels termed ``lanceolate hair'' (lah),
which maps in the vicinity of a cluster of desmosomal genes on
mouse chromosome 18q, was thought to be an animal model
for NTS (Montagutelli et al, 1996; Sundberg et al, 2000);
however, linkage analysis in ®ve NTS families excluded the
homologous region on human chromosome 18q12 as well as
other candidate gene regions (Sprecher et al, 2000). NTS was
®nally mapped by genome-wide screening to a 4 cM interval
on chromosome 5q32 (Chavanas et al, 2000a), and several
patients, most resulting from consanguineous matings, were
found to carry mutations in SPINK5 (Chavanas et al, 2000b).
This gene, 61 kb in size, consists of 33 exons and encodes a
recently discovered Kazal-type serine protease inhibitor (desig-
nated LEKTI) (Chavanas et al, 2000b; MaÈgert et al, 1999). We
studied an international cohort of 19 NTS families and report
here novel and recurrent mutations with signi®cant implications
for the development of successful mutation detection strategies
as well as the ®rst prenatal diagnosis of NTS.
MATERIALS AND METHODS
Patients and clinical material We ascertained 19 NTS families,
including 21 affected individuals, with their informed consent. The
diagnosis of NTS was based on the presence of the following features: (i)
CIE-like ichthyosis or ILC (Fig 1A, B); (ii) hair shaft abnormalities,
including trichorrhexis invaginata (Fig 1C), trichorrhexis nodosa, or pili
torti; and (iii) elevated IgE levels, and/or history of recurrent bacterial
infections, malnutrition, neonatal dehydration, and allergies. To compare
the severity of the disease between individuals, we developed a severity
score (see Table I) based on the following criteria: skin involvement
(ILC or eczema of < 30% of body surface = 1, ILC or eczema of > 30%
of body surface = 2, generalized scaling erythema or eczema = 3); hair
shaft abnormalities (none = 1, mild = 1, severe = 2); IgE levels
Figure 1. Clinical features of NTS. (A) Ichthyosis linearis
circum¯exa. Note the circinate hyperkeratotic plaques bordered by a
characteristic double-edged scale. (B) Generalized CIE-like ichthyosis in
NTS. (C) Trichorrhexis invaginata. Note the typical ball-and-socket
appearance of the hair shaft.
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Table I. Clinical features and severity of NTS
Family Ethnic origin Age
Skin involvement
Hair shaft abnormalities
(TI, PT, TN) Serum IgE levels (IU/ml) Associated Features Severity
score
1 2 3 1 2 1 2 3
ILC/
Eczma
(<30%)
ILC/
Eczma
(>30%)
Gener.
CIE-like
ichthyosis Mild Severe
100±
1,000
>1,000±
10,000 >10,000
Postnatal
Hypernatr.
Dehydration
Postnatal
Failure to
Thrive
Growth
Retardation/
Enteropathy
Severe
Recurr./
Systematic
Infections
Allergic
reactions
(food/
pollen)
1 Italian 5 2 1 2 0 0 0 1 1 7
2 German/
Irish 16 1 1 2 1 0 0 0 1 6
3 English/
Italian 7 2 2 2 0 0 0 1 1 8
4 Northern European 5 2 1 2 0 1 0 1 1 8
5 Irish/
Scottish 12 3 2 3 1 1 1 1 1 13
6 Dominican
Republic 18 3 2 3 0 1 1 1 1 13
7c Puerto-Rican 8 3 2 N/A 0 1 1 1 0 [8]
8c Iranian 3 3 1 N/A 2 0 1 0 0 1 [8]
9 African-American 17 3 2 3 0 1 0 1 1 11
2 2 2 2 0 1 0 1 0 8
10 Northern European 13 3 1 2 1 1 1 1 1 11
11 Italian/Finnish 33 2 2 2 0 0 0 1 1 8
12 Northern European 4 1 2 1 0 1 0 1 1 7
6 1 2 1 0 0 0 1 1 6
13 Argentinian 12 1 1 2 1 1 0 1 1 8
14 German 55 2 2 2 0 0 0 0 1 7
15 German/
Northern European 13 2 2 2 1 1 0 1 9
16 Polish/
Romanian 6 1 1 2 0 1 0 1 0 6
17 German/Northern European 5 3 2 3 0 1 0 1 1 11
18 Northern
European 3 3 1 1 1 0 0 1 1 8
19 Northern
European 2 3 1 1 1 1 0 1 1 9
ILC, ichthyosis linearis circum¯exa; CIE, congenital ichthyosiform erythroderma; TI, trichorrhexis invaginata; TN, trichorrhexis nodosa; PT, pili torti; c, consanguineous family; N/A, not analyzed.
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(< 100 IU per ml = 0, 100±1000 IU per ml = 1, > 1000±10,000 IU per
ml = 2, > 10,000 IU per ml = 3), associated features (absent = 0,
present = 1). Our cohort comprised 12 multiplex families and seven
families with a single affected child, including two consanguineous
families. The families were of northern European, African-American,
Mediterranean, Iranian, South American, and Puerto-Rican descent.
Peripheral blood samples and/or buccal swabs of all participants were
collected and prepared for DNA analysis following standard procedures.
Microsatellite analysis Twelve multiplex NTS families (57
individuals, 18 affected) were initially included in the linkage studies. We
selected four polymorphic microsatellite markers spanning 12 cM on 5q
derived from the GDB database, including: cen±D5S436±3 cM±
D5S2090±2 cM±D5S434±7 cM±D5S410±tel. Genotypes of all family
members were determined by polymerase chain reaction (PCR)
ampli®cation of genomic DNA (gDNA) using ¯uorescently labeled (6-
FAM, HEX, NED phosphoramidite), tailed primers and Ampli Taq
Gold (PE Applied Biosystems, Foster City, CA), according to the
manufacturer's instructions. The amplicons were separated by
polyacrylamide gel electrophoresis on an ABI Prism 377 sequencer, and
genotypes were established using the GeneScan 3.1 and GenoTyper 2.0
software (PE Biosystems). Genotypes were used to construct the most
parsimonious haplotype for each family member. Multipoint LOD scores
were computed with GENEHUNTER (Kruglyak et al, 1996). Allele
frequencies for markers were obtained from the GDB database or our
data. NTS was modeled as an autosomal recessive disorder with
complete penetrance and disease allele frequency of 0.00001.
Mutation analysis Mutation analysis of SPINK5 was performed using
primer pairs as previously described (Chavanas et al, 2000b) and/or
newly designed (exons 1, 9, 11, 16, 31, and 33) from the partial
sequences of SPINK5 (GenBank accession no. AJ270994, AJ391230±
AJ391254, AJ276577±AJ276580). To design primers for exons 8 and 10,
we established the intronic boundaries of those exons (sequences are
deposited in GenBank under accession nos AF295783and AF295784) by
amplifying gDNA with the Expand Long Template PCR system
(Boehringer Mannheim, Indianapolis, IN) and intraexonic primers of
exon 10 (forward 5¢-GTA ACA TGA AGA TCG GAA GCG TCT C-
3¢), exon 8 (forward: 5¢-GAA AAT GCC AAG CGA GAG GGT
GAA AC-3¢; reverse: 5¢-CTT TTC AGC ATT TCG TCG AAT TCT
AG-3¢) as well as primers located in introns 6 (forward), 8 (reverse) and
10 (reverse) (Table II). The gDNA of affected individuals was PCR
ampli®ed using the above speci®ed primers with Taq polymerase and Q
solution (Qiagen, Valencia, CA) or AmpliTaq Gold, GeneAmp PCR
Buffer II and 2% dimethyl sulfoxide (Table II). Cycling conditions were
95°C 5 min followed by 35 cycles at 95°C 30 s, 57±60°C 45 s, 72°C
90 s; and a ®nal extension step at 72°C for 7 min.
These PCR products were mixed 1 : 1 with amplicons obtained from
healthy controls before screening for sequence alterations by hetero-
duplex analysis using conformation-sensitive gel electrophoresis (CSGE,
6% polyacrylamide gels) (KoÈrkkoÈ et al, 1998). Amplicons with divergent
migration patterns on CSGE were gel-puri®ed (QIAquick gel extraction
kit, Qiagen) and subjected to bi-directional DNA sequencing using the
BigDye terminator system on an ABI Prism 377 sequencer (PE Applied
Biosystems). If no evidence for mutations was obtained by heteroduplex
analysis, we subsequently analyzed all fragments by direct DNA sequen-
cing. Each sequence variant was con®rmed by restriction fragment
analysis, CSGE or sequencing, and excluded from 50 to 120 alleles of
unrelated control individuals.
Electronic database information GDB database, http://gdbhttp://
www.gdb.org; GenBank, http://www.ncbi.nlm.nih.gov (accession
numbers for SPINK5: AJ270994, AJ391230±AJ391254, AJ276577±
AJ276580, AF295783, and AF295784); Online Mendelian Inheritance in
Man (OMIM), http://www.ncbi.nih.gov/Omim/.
Table II. Genomic primer sequences for ampli®cation of SPINK5 (exons 1-33)a
Exon Upstream primer Downstream primer
Amplicon
size (bp)
Annealing
temperature
Taq PM
systemb
1 CAATGCATGGAGTGGACCTGT AGACATTTCAGGATTATACATGC 229 60 Q
2 GTGCCCTTCTTTTATTTGCCATG AAAGCTATTAGTACCTACCAG 248 60 Q
3 TATCTACTATGTATCAGGCATTC ATTTACCAGTTCAGAGACTAGC 371 60 Q
4 ATCTGGGGTTCTGTGTCCAC CAGGTATGACCTAGTAATTAAG 327 57 Q
5 TATTAGCTCAATGTAGCCTTC TGTAGGGAAAATTGTGTGTCATG 349 60 Q
6 TAAAGGAGAATGACAATGCAATG TACTATTTGAAGTTAGCCTCCC 215 60 Q
7 AGTACTTACTGAGCTACATCTAC TTATCTCTCTGCTGAGTGATTC 358 60 Q
8 CGTAGCAGAGGATATGAAAGTG GAGAAACACAGGTGGAAACGTCAC 393 60 Q
9 GGAAGGATCTCTGAGCCTAG GCATTATGATTTGTGGAGGGC 424 60 Q
10 CTAAAACTCAGGACAACTTAG CAATAGCTACCACACATCGAAGAC 521 57 Q
11 GAAAACAGAACTATATCTCAACT CTGTCTTGAGCCACAGTCTC 272 57 AG
12 GAAGAAATCATAGCACCATAC GCAAAATCTCACCCTTTAGGC 349 60 Q
13 GAGATGTAACATTAGTTTCTGC ATGTCTCCAATCAGACAGTTTCTC 370 60 Q
14 TGCAATTGTGAGGATTTCACAG CCTGAACATGATCTGTGGATC 304 60 Q
15 AATCCATGCCTTCAAAGTTAATC CCAAGACTGAATGCTACACTG 392 60 Q
16 TGAGGCAGGAAGAATTGCTTG GTGAAATAAAATTGGTACTCTGGACAC 244 57 AG
17 CTGATTGATGACGGAACCTTTG CTCACGGTCTATACTCTAC 389 60 Q
18 CAAAAGCACCTCTCAGACTAG AGTACTCTTGTATATGGGGATC 380 60 Q
19 TTCCAAATGTGTGACCTAGTTC CAAACTCAGTGCAAAGACAGC 432 60 Q
20 GTTTACCTTTCCACTCCAAAGC TGAACCCCTAGTTCCCTCAC 319 60 Q
21 GAATACAGCCACCTTCTTAAG AATACATATTATTTGCCTGGCTC 392 60 Q
22 AGAGAAGGCCTGCAGCATAG AGCACTGCCTTTACCATAGAC 344 60 Q
23 CCACCGTACCCGGCAATG TGCATCCAAGGAGCCATA 378 60 Q
24 GTGCCAGAATCCTAGGAAGAC CTAGCTTGATCATGTTGACACC 332 60 Q
25 ATTATTTTGCCTATCACAGCAAG TCATTAATTACCAGATCTGCTTC 372 60 Q
26 TGACTGTGAGTCTTAAAGTAC GGGACAGAGTCAGCATTTCAC 252 60 Q
27 TCTGTTTTTTTCCTGTGTTATGAGT GTGTGATGCCAAGTATCTTAGG 335 60 Q
28 CCAACAATCAGAACTGATTAGC CAAAGTGACAAGACAAGAAAAATC 389 60 Q
29 GGCCTCTGTTGCCAGGATG TATACAAACTTATTCAAGCAGCAG 347 60 Q
30 GCCTGGGCCTTCCAAAAT ACTTCAGGCTGCACTGAATCA 379 60 Q
31 GTGCAAAATCAATCTTTGAGTTTG CTAAACTGGAAGATATGATGGG 324 60 Q
32 GACACCTGGATGATACCTAC CCAGATAAATGTCCATTACTCAG 365 60 Q
33 CTAGCATCTAACCTACCCATC GCAAATAAGACAAGCTCCGAAG 148 60 Q
aThe primers were placed on ¯anking intronic sequences at least 25bp from the exon-intron borders.
bQ = Qiagen Taq: AG = Perkin Elmer Ampli Taq Gold.
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RESULTS
Clinical features of NTS We examined a total of 21 affected
individuals aged 2±55 y with NTS from 19 families of diverse
ethnic backgrounds (Table I). In all but one patient NTS
manifested at birth with scaling erythroderma. In one family, a
sibling diagnosed with ``ichthyosis'' and severe failure to thrive died
at 2 y of age of unknown cause (family 8, Table I). The
dermatologic features at the time of examination covered a wide
spectrum ranging from a few localized, erythematous plaques with
scaling borders to generalized erythroderma with ®ne, white scales
reminiscent of CIE. All affected individuals had also hair shaft
abnormalities, including trichorrhexis invaginata (Fig 1C),
trichorrhexis nodosa, and pili torti. Patients from nine families
had severe manifestations, including CIE-like, generalized skin
involvement, short, sparse hair, a history of failure to thrive and/or
growth retardation, postnatal dehydration, enteropathy, and
systemic infections (Table I). Their cutaneous features included
generalized erythema, ®ne white scaling (Fig 1B) often associated
with sheet-like peeling of the stratum corneum resembling peeling
skin syndrome. A distinct group of 12 patients had only localized
skin lesions, ILC (Fig 1A) and/or eczematous plaques and ¯exural
licheni®cation reminiscent of atopic dermatitis, less often associated
with other organ manifestations. The type of disease was consistent
for affected siblings in our cohort despite some phenotypic
variability in severity. There was considerable overlap with
symptoms of the atopic spectrum. All patients reported persistent
pruritus, 18 had a history of allergic reactions to food and/or
pollens, and ®ve had asthma. Whereas most patients had elevated
IgE levels above 1000 IU per ml, only patients with CIE-like
ichthyosis exhibited extreme elevations (> 10,000 IU per ml).
Mutation analysis of SPINK5: Altered protein translation
due to splice site, nonsense or frameshift mutations On
account of the observed phenotypic heterogeneity of NTS, we
decided to test our cohort for linkage to the NTS locus in 12
multiplex families amenable to this approach. Using multipoint
linkage analysis, we con®rmed mapping of NTS to 5q32 (maximal
LOD score of 4.4 at locus D5S434), providing convincing evidence
for locus homogeneity across families of diverse genetic
backgrounds (data not shown).
Using heteroduplex analysis and direct DNA sequencing, we
analyzed the gDNA of 19 unrelated NTS patients for sequence
variations in SPINK5 as exempli®ed in Fig 2. We identi®ed 17
distinct mutations, 15 of which had not been reported previously
(Table III, Fig 3). The mutations were distributed across the
entire gene, although eight of 17 (47%) clustered between exons 2
and 8, which encode the signal peptide and the ®rst three putative
inhibitory domains of LEKTI. The majority were private muta-
tions, although we observed three recurrent nucleotide alterations:
2264insA occurred in two families of African-American and
northern European origin, and 81+2T®A segregated in two
unrelated families of northern European descent (Fig 3); patients of
two consanguineous families from Iran and Puerto-Rico were
homozygous for 238insG, whereas another affected individual of
Italian background was heterozygous for this mutation.
The mutational spectrum included small deletions and insertions
(n = 8), splice site (n = 5) and nonsense mutations (n = 4)
(Table III). All these mutations can be predicted to disrupt
signi®cantly the amino acid sequence of the translated LEKTI
protein either by introducing a premature termination codon as
result of a frameshift or nonsense mutations, or by altering
conserved consensus RNA splicing signals. Similar to previously
reported data (Chavanas et al, 2000b), we obtained evidence for
nonsense mediated mRNA decay using semiquantitative reverse
transcription±PCR from RNA of cultured keratinocytes of a
patient in family 6 (Table III) (data not shown). Although RNA
samples of patients with splice site defects were not available for
analysis, all mutations eliminated invariant splice donor or acceptor
sites and are, therefore, expected to produce abnormal splice
products.
Only 12 of 25 mutant alleles were detected by CSGE screening
(Fig 2), re¯ecting a sensitivity of about 50% for this screening
method. Subsequent direct DNA sequencing of the entire coding
region and ¯anking splice sites of SPINK5 in the remaining disease
alleles revealed 13 additional mutations and a large number of
nonconsequential polymorphisms mainly in the noncoding regions
of SPINK5 (data not shown). Nevertheless, we did not identify any
pathogenic sequence variation in 13 disease alleles of patients from
eight unrelated NTS families. It is possible that these patients carry
mutations in the 5¢ regulatory region of the gene, within introns, or
in the carboxy-terminal untranslated region, which may alter
expression or function of the protein.
We compared our molecular data with the clinical presentation
of NTS in our cohort (Tables I and III). Our analysis revealed that
Figure 2. Representative example of mutation screening of
SPINK5. (A) DNA obtained from affected individuals of different
families was ampli®ed with primers speci®c for exon 22 of SPINK5.
PCR products were analyzed using CSGE as described in Materials and
Methods. Results show abnormal migration of PCR product obtained
with DNA from an affected individual of family 2 (arrow). (B) Direct
sequencing of this PCR product revealed a heterozygous 9-bp deletion
across the 3¢ intronic boundary of exon 22 (arrow) predicted to eliminate
the splice donor site and leading to partial translation of intron 22
(premature termination codon 20 residues downstream of the mutation).
(C) Segregation of the mutation throughout the family was veri®ed using
digestion with MslI DNA endonuclease. As the mutation abolishes a
restriction site for this enzyme, the patient (®lled symbol) as well as his
father demonstrate both an uncut fragment (339 bp) and two cut
fragments (241 bp and 98 bp).
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the presence of homozygous frameshift and splice site mutations
toward the 5¢ end of SPINK5 (81 + 2T®A, 238insG,
391insCGTG) resulted in a severe phenotype with generalized,
CIE-like skin manifestation (families 5, 6, 7, and 8). These
mutations are predicted to interrupt LEKT1 and to eliminate
almost all KAZAL-like domains rendering the protein nonfunc-
tional (null alleles); however, the phenotype of NTS patients who
were compound heterozygotes for a premature termination codon
or splicing mutation was variable, and did not allow drawing any
de®nitive genotype±phenotype correlations.
Prenatal diagnosis of NTS A 32 y old healthy mother of two
children, one of which has NTS (family 4 in Table I), was referred
to our study in the seventh gestational week of her third pregnancy.
Mutation analysis of SPINK5 demonstrated that the affected child
was compound heterozygous for two SPINK5 mutations, each
inherited from one parent (Table III). The maternal mutation
475-2 A®G alters a consensus splice acceptor site and is predicted
to result in skipping of exon 7. The paternal mutation, 2264insA
results in a frameshift introducing a premature termination codon 1
amino acid downstream of the mutation site (Fig 4A). This
mutation could lead to the synthesis of a truncated translation
product or to the absence of protein (null allele) as a consequence
of non-sense mediated mRNA decay. In addition to these
mutations, each parent carried a heterozygous nonconsequential
sequence polymorphism, the father a T®C substitution in intron
23 at position 2241-26, and the mother a silent polymorphism
R177R (531G®A transition) in exon 7. In contrast to the affected
child, who inherited both mutations but neither polymorphisms,
the unaffected sibling carried only the polymorphisms. Therefore,
we were able to establish the phase and determine that the
nondisease associated polymorphisms were located on the parental
wild-type allele (Fig 4B). Prenatal diagnosis was performed on
gDNA extracted from fetal chorionic villi obtained by CVS at the
12th week of pregnancy. Direct DNA sequencing of SPINK5
amplicons harboring the known sequence variants revealed the
absence of both pathogenic mutations but presence of both
sequence polymorphisms in the fetus (Fig 4A). These results ruled
out a possible contamination of the tested sample with maternal
cells, and conclusively determined that the fetus was unaffected
(Fig 4B). As predicted, the mother gave birth to a healthy child.
Our data demonstrate the feasibility of prenatal diagnosis for NTS
and also underscore that intragenic polymorphic sites can be
valuable assets assisting genetic testing.
DISCUSSION
Protease inhibitors play a central part in the maintenance of many
physiologic functions such as food digestion, blood coagulation,
and extracellular matrix remodeling by limiting unwanted
proteolytic activities and thereby regulating cell migration, pro-
liferation, and differentiation. Serine protease inhibitors comprise
four families, serpins, leuko-proteases, Kunitz type and Kazal type
serine protease inhibitors (Bode and Huber, 1992; Roberts et al,
1995). The latter family is characterized by three conserved
disul®de bonds and a reactive site loop of each inhibitory domain,
for which pancreatic secretory trypsin inhibitor is a prototype
(Roberts et al, 1995). Pancreatic secretory trypsin inhibitor has only
a single active domain that targets trypsin, whereas other avian
Kazal-type serine protease inhibitors have multiple inhibitory
domains (up to seven) with different speci®cities for trypsin,
chymotrypsin, elastase, and subtilisin, and might have the potential
to inhibit these simultaneously (Saxena and Tayyab, 1997). LEKTI
contains an unprecedented number of 15 inhibitory domains, two
of which represent classical Kazal sites. The remaining 13 Kazal-like
domains, one of which was shown to inhibit trypsin in vitro, contain
only two intramolecular disul®de bonds (MaÈgert et al, 1999).
Nevertheless, the actual physiologic substrates of LEKTI are
currently unknown.
The results of this study (Table III) con®rm the recent report by
Chavanas et al (2000b) and unequivocally establish that mutations in
SPINK5 and subsequent elimination/inactivation of the serine
protease inhibitor LEKTI are the molecular cause of NTS. The
pathomechanisms leading to this complex disease, however, remain
to be elucidated. As SPINK5 is highly expressed in the thymus
(MaÈgert et al, 1999), defective LEKTI expression might have a
deleterious effect on T-cell differentiation, thus explaining the
unbalanced Th2 immune response with markedly elevated IgE
levels and the increased susceptibility to infections characteristic for
NTS. It is also possible that like other serine protease inhibitors
LEKTI is expressed as part of a cytokine-activated acute-phase
response to trauma and against bacterial and chemical assaults
(Yasuda et al, 1993; Roberts et al, 1995).
A wide variety of protease inhibitors, including LEKTI are
expressed in the skin (Abts et al, 1999; Alkemade et al, 1994; Scott
et al, 1998; Cui et al, 1999), suggesting that these enzymes may be
crucial for controlling epidermal cell growth and differentiation.
Pathogenic mutations in the cathepsin C gene, which encodes a
protease expressed in epithelial tissues, have been shown to underlie
two genodermatoses, Papillon±Lefevre syndrome (MIM 245000)
Figure 3. Spectrum of mutations in SPINK5. Mutations are indicated along a schematic representation of the LEKTI polypeptide. Typical Kazal-
type domains are represented in red, other Kazal-like domains are depicted in blue. The N-terminal secretory signal peptide is colored in yellow.
Mutations reported in the present study appear above the diagram, and previously reported mutations (Chavanas et al, 2000b) appear below the diagram.
Mutations that were observed more than once are underlined, and the number of unrelated families carrying this mutation is shown in parenthesis.
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Figure 4. Prenatal diagnosis of NTS. (A) Two mutations were detected in the gDNA of the affected child in family 4, an insertion mutation
carried by the father (2264insA) and a splice site mutation carried by the mother (475-2 A®G). Neither mutation was present in the 12 wk old fetus
as tested from chorionic villi samples. (B) Summary of mutation analysis in all members of family 4. Note the presence of distinct heterozygous
polymorphic markers in both parents. Both polymorphisms were present in the unaffected fetus and a healthy sib, whereas they were absent in the
affected child, thus indicating that they must be carried on the normal maternal and paternal alleles.
Table III. Spectrum of mutations in SPINK5
Family Mutations Location Nucleotide change Veri®cation Predicted consequenceb
1 238insG Exon 4 GGGCC®GGG GCC CSGE/sequencing PTC + 18
Q46X Exon 3 CCCAG®CCTAG +StyI PTC
2 2017del9 Exon 22 ACTCAGgtgag®Ag -Ms1I Altered splicing
G103X Exon 5 AAGGAG®AATGAG CSGE/sequencing PTC
3 2579del9 Exon 27 GAAAG®GAAG CSGE/sequencing PTC + 63
1888-1 G®A Intron 20 tagGAG®taaGAG + MseI Altered splicing
4 475 ±2 A®G Intron 6 cagGAT®cggGAT -Eco571 Altered splicing
2264insA Exon 24 AAGGAG®AATGAG CSGE/sequencing PTC + 1
5 81+2 T®A Intron 2 Aggtt®Aggat CSGE/sequencing Altered splicing
81+2 T®A Intron 2 Aggtt®Aggat CSGE/sequencing Altered splicing
6 391insCGTG Exon 5 TGCA®TGCGTGCA CSGE/sequencing PTC + 4
391insCGTG Exon 5 TGCA®TGCGTGCA CSGE/sequencing PTC + 4
7c 238insG Exon 4 GGGCC®GGG GCC CSGE/sequencing PTC + 18
238insG Exon 4 GGGCC®GGG GCC CSGE/sequencing PTC + 18
8 c 238insG Exon 4 GGGCC®GGG GCC CSGE/sequencing PTC + 18
238insG Exon 4 GGGCC®GGG GCC CSGE/sequencing PTC + 18
9 392insGTG Exon 5 GCAC®GCGTGCAC CSGE/sequencing PTC = 4
2264insA Exon 24 AAAAT®AAAAAT CSGE/sequencing PTC + 1
10 81+2 T®A Intron 2 Aggtt®Aggat CSGE/sequencing Altered splicing
1024ins5 Exon 12 AAG®AGAAAAAAG CSGE/sequencing PTC + 29
11 2240+1 G®A Intron 23 ATTgta®ATTata CSGE/sequencing Altered splicing
R218X Exon 8 GACGAA®GATGAA CSGE/sequencing PTC
12 1151delGA GAGAAC®GAAC CSGE PTC + 19
?
13 2212+1 G®A Intron 22 CAGgtg®CAGatg -HphI Altered splicing
?
14 R578X Exon 19 ATGGAC®ATTGAC +FokI PTC
?
15
16
17
18
19
aNumbers denote amino acid positions of nonsense mutations or cDNA nucleotide position (starting from ATG) for other mutations.
bPTC + n = premature termination codon occurring n residues downstream to the mutation.
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and Haim±Munk syndrome (MIM 245010) (Hart et al, 2000;
Toomes et al, 1999; Nakano et al, 2001). The function of proteases
and their inhibitors might be particularly important for proper
desquamation, which requires the proteolytic dissolution of
intercellular cohesive structures in the stratum corneum
(Lundstrom and Egelrud, 1990). Several proteases such as the
stratum corneum trypsin-like serine protease (Ekholm et al, 2000)
and stratum corneum chymotryptic enzyme (Horikoshi et al, 1999;
Eckholm and Egelrud, 2000) are thought to play a pivotal part
during this process, which could potentially be controlled by
LEKTI.
We identi®ed 17 distinct SPINK5 mutations in our international
cohort of NTS patients. All of the mutations can be predicted to
truncate or disrupt the mutant LEKTI protein due to premature
termination of translation or generation of altered splice products,
respectively. It is conceivable that missense mutations in SPINK5
occur but do not manifest clinically due to the unusual large
number of repetitive protease inhibitory domains of LEKTI (15
sites) resulting in functional redundancy (MaÈgert et al, 1999). In
contrast, missense mutations of SPINK1, which encodes a protein
with a single Kazal domain, were found in both hereditary and
sporadic forms of chronic pancreatitis (Witt et al, 2000).
Including this report, a total of 26 distinct SPINK5 mutations
have been identi®ed to date (Fig 3). Small insertions (n = 8) and
splice mutations (n = 8) account for the majority, whereas small
deletions (n = 5) and nonsense mutations (n = 5) were somewhat
less common. Our study con®rmed that most pathogenic mutations
are private and occur throughout the gene. Of note, however, is
that three mutations were identi®ed in two or more unrelated
families from different genetic backgrounds (238insG, 81 +
2T®A, 2264insA). As two of these sequence alterations were
located within three (238insG) and six (2264insA) mononucleotide
repeats, slipped mispairing at the replication fork may account for
their repeated occurrence. 238insG in exon 4 and 1888±1G®A in
intron 20 were previously reported by Chavanas et al (2000b) who
also identi®ed mutation 2468insA in exon 26 in three unrelated
families. Cumulative data in Fig 3 illustrate that 46% of all 26
identi®ed mutations cluster between exons 2 and 9, accounting for
almost half of all disease alleles (40%). Thus, our mutation detection
strategy includes an initial analysis of exons 4 and 5, followed by
exons 1±3, and ®nally exons 6±33. The considerable size of the
SPINK5 gene indicates the need for a powerful presequencing
screening method. We found the sensitivity and ef®cacy of CSGE
not satisfying, but denaturing high performance liquid chromato-
graphy, which has reportedly a high sensitivity between 95% and
100% (Ellis et al, 2000; Jones et al, 1999), may prove of value for
future mutation screening of SPINK5.
Regardless of the evidence for locus homogeneity in NTS and
despite sequence analysis of the entire coding region, we were
unable to detect pathogenic SPINK5 mutations in 34% of the
disease chromosomes. Most likely, mutations in untranslated
portions of the gene affecting protein expression, including
promoter region, regulatory intronic sequences, and distal
3¢UTR could account for the disease. It will be challenging to
screen these regions because of the large size of SPINK5 introns (on
average 1.5 kb) and the great number of nonconsequential
sequence variants within these regions (data unpublished).
Alternatively, large deletions or rearrangements of SPINK5,
which would not be readily detectable with PCR-based screening
methods, may occur; however, the presence of several hetero-
zygous sequence polymorphisms in the genomic sequence of
SPINK5 in most affected individuals (data not shown) renders this
hypothesis less likely.
Genotype±phenotype correlations in our cohort revealed that
homozygous frameshift and splicing mutations predicted to result in
early truncation of LEKT1 were associated with severe disease and
in one case (family 8) fatal outcome (Tables I and III); however,
an affected individual compound heterozygous for such mutations
in exons 3 and 4 displayed a relatively mild phenotype with ILC
skin manifestation (family 1, Tables I and III). As both ILC and
CIE-like features have been reported in affected siblings who
presumably carry identical mutation(s) (Traupe, 1989), it is likely
that other genetic and/or epigenetic factors contribute to the
phenotype, which should be considered for genetic counseling of
NTS families.
The elucidation of SPINK5 mutations as the proximal cause of
NTS has broken the ground for the molecular diagnosis of this
complex disease and allows for improved genetic counseling. As
attested by our study, it is now possible to perform successfully
prenatal diagnosis of NTS as early as in the 10th to 12th gestational
week when the disease-causing SPINK5 mutations of the family
can be established. The feasibility of prenatal testing will without
doubt be of considerable bene®t to NTS families with children
suffering from a severe or even fatal disease. On the other hand,
future molecular testing could strongly facilitate timely diagnosis of
NTS in patients with neonatal and infantile erythrodermic
ichthyosis or with equivocal clinical features. A systematic inves-
tigation of families with NTS or atopic diathesis for SPINK5
mutations may eventually shed light on the long-debated relation-
ship between NTS, atopic eczema, and asthma.
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